Systemic embolism in amyloid transthyretin cardiomyopathy
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2566
Abstract: Although systemic embolism is a potential complication in transthyretin amyloid cardiomyopathy (ATTR‐CM), data about its incidence and prevalence are scarce. We studied the incidence, prevalence and factors associated with embolic events in ATTR‐CM. Additionally, we… read more here.
Keywords: systemic embolism; amyloid transthyretin; embolism amyloid; embolism ... See more keywords
Left ventricular hypertrophy, dilatation and ejection fractions predict ventricular tachycardia in amyloid transthyretin cardiomyopathy
Sign Up to like & getrecommendations! Published in 2023 at "Europace"
DOI: 10.1093/europace/euad122.274
Abstract: Abstract Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Pfizer Global Medical Grant Background Amyloid transthyretin cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy caused by extracellular deposition of amyloid fibrils. The disease… read more here.
Keywords: ventricular tachycardias; amyloid transthyretin; ventricular tachycardia; transthyretin cardiomyopathy ... See more keywords
Amyloid transthyretin cardiac amyloidosis with different manifestations, test findings and types
Sign Up to like & getrecommendations! Published in 2023 at "BMJ Case Reports"
DOI: 10.1136/bcr-2022-250972
Abstract: Amyloid transthyretin amyloidosis usually presents with cardiac amyloidosis manifestations, most commonly with a heart failure syndrome. The history and physical examination offer clues of other cardiac and extracardiac manifestations. Taking a detailed history is essential… read more here.
Keywords: different manifestations; cardiac amyloidosis; amyloidosis different; amyloid transthyretin ... See more keywords